PULSE BIOSCIENCES, INC. — Director's Dealing 2023

Nov 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2023-11-13

Reporting Person: Zanganeh Mahkam (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-13	Common Stock	M	20000	$2.14	Acquired	548836	Direct
2023-11-13	Common Stock	M	56075	$2.14	Acquired	604911	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-13	Stock Option (right to buy)	$2.14	M	20000	Disposed	2032-05-19	Common Stock (20000)	Direct
2023-11-13	Stock Option (right to buy)	$2.14	M	56075	Disposed	2032-05-19	Common Stock (56075)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	27000	Indirect
Common Stock	14000	Indirect
Common Stock	107074	Indirect

Footnotes

F1: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2022 Annual Stockholder Meeting.

F2: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quartetrly basis following the Company's 2022 Annual Stockholder Meeting.